7 completed, 1 active not recruiting, 1 unknown. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 7, Active not recruiting 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Urethral Neoplasms: new trials by email Literature Review of Urethral Neoplasms trials Research Report on Urethral Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-10-26 |
| Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Treatment duration of cisplatin based chemotherapy - Bladder Cancer, Ureter Cancer | Phase 3 | Unknown | Asan Medical Center | 330 | 2016-09-01 | 2017-09-28 |
| A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Ramucirumab, Docetaxel, Placebo - Urothelial Carcinoma | Phase 3 | Completed | Eli Lilly and Company | 530 | 2015-07-13 | 2023-08-21 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Bevacizumab, Cisplatin, Gemcitabine Hydrochloride - Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 506 | 2009-07-15 | 2026-06-24 |
| Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Fentanyl sublingual spray, Placebo - Cancer | Phase 3 | Completed | INSYS Therapeutics Inc | 130 | 2007-10-01 | 2014-03-05 |
| Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer cisplatin, gemcitabine hydrochloride, paclitaxel - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 608 | 2001-05-01 | 2013-06-12 |
| Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium carboplatin, gemcitabine hydrochloride, methotrexate - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 / Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 238 | 2001-01-01 | 2013-06-12 |
| Combination Chemotherapy in Treating Patients With Bladder Cancer carboplatin, cisplatin, doxorubicin hydrochloride - Bladder Cancer, Urethral Cancer | Phase 3 | Completed | Eastern Cooperative Oncology Group | 490 | 1999-04-02 | 2023-06-15 |
| Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium carboplatin, cisplatin, doxorubicin hydrochloride - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 3 | Completed | Eastern Cooperative Oncology Group | 330 | 1998-12-03 | 2023-06-22 |
Urinary Bladder Neoplasms (8) · Carcinoma, Transitional Cell (3) · Ureteral Neoplasms (3) · Prostatic Neoplasms (2) · Adrenocortical Carcinoma (1) · Anus Neoplasms (1) · Appendiceal Neoplasms (1) · Astrocytoma (1) · Bile Duct Neoplasms (1) · Blast Crisis (1) · Brain Neoplasms (1) · Breast Carcinoma In Situ (1) · Breast Neoplasms (1) · Breast Neoplasms, Male (1)
Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Male Urogenital Diseases (9) · Neoplasms by Site (9) · Urethral Diseases (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Urologic Diseases (9) · Urologic Neoplasms (9) · Neoplasms (8) · Urinary Bladder Diseases (8) · Carcinoma (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Ureteral Diseases (3)
Cisplatin (4) · Carboplatin (3) · Gemcitabine (3) · Methotrexate (3) · Paclitaxel (3) · Vinblastine (3) · Doxorubicin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Bevacizumab (1) · Disulfides (1) · Docetaxel (1) · Fentanyl (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Platinum (1)
Eastern Cooperative Oncology Group (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · National Cancer Institute (NCI) (2) · Asan Medical Center (1) · Eli Lilly and Company (1) · INSYS Therapeutics Inc (1)
United States (7) · Belgium (3) · Canada (3) · Denmark (3) · Germany (3) · Hungary (3) · Israel (3) · Italy (3) · Netherlands (3) · Poland (3) · Spain (3) · United Kingdom (3) · Australia (2) · Austria (2) · France (2)
Bruce J. Roth, MD (2) · Andreas Boehle, MD (1) · Christoph Zielinski, MD (1) · David C. Smith, MD (1) · Gerwin Kaiser, MD (1) · Jae-Lyun Lee, MD., PhD. (1) · Joaquim Bellmunt, MD, PhD (1) · Jonathan E Rosenberg (1) · Jose Baselga, MD (1) · Larry Dillaha, MD (1) · Malcolm J. Moore, MD (1) · Martin J. Edelman, MD (1) · Michael Leahy, MBChB, FRACP, FRCP, FRC Path (1) · Shilpa Gupta (1)
PMID 11001674, PMID 15073851, PMID 1607913, PMID 16330205, PMID 18024869, PMID 18685414, PMID 19786668, PMID 22162575, PMID 22370319, PMID 22480131, PMID 26001531, PMID 27020837, PMID 28916371, PMID 31753727, PMID 33160359, PMID 33989025, PMID 34795131, PMID 35388003, PMID 40256659, PMID 40591902
U10CA180821 (2), 2014 (1), U10CA031946 (1)